Summit Therapeutics Inc. (SMMT)
SMMT moved a median of +0.03% 30 minutes after news, and +0.06% by the close. How SMMT actually reacts to news — the realized, point-in-time move the market made, measured across 426 labeled events over the last three years with zero look-ahead.
SMMT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.05% | 51% | 423 |
| 30-min | +0.03% | 50% | 424 |
| 60-min | +0.09% | 51% | 425 |
| to close | +0.06% | 51% | 417 |
| Middle 50% of SMMT reactions | -1.53% to +1.71% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 426 |
Half of all Summit Therapeutics Inc. news events land between -1.53% and +1.71% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SMMT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 28 | -0.76% | 39% | -1.28% |
| Analyst downgrades | 16 | -0.44% | 31% | -0.49% |
| Coverage initiations | 62 | +0.40% | 60% | +1.59% |
| Rating reiterations | 94 | -0.22% | 46% | -1.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SMMT ranks against every other measured name →
That’s how SMMT usually reacts — get an email when it moves on news →Email me when SMMT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SMMT's baseline. Nothing else.
Recent SMMT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A Summit Therapeutics Inc. For: Oct 06 | SEC filing · Form PRE | SEC EDGAR | -0.64% | +4.79% | |
| AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics | Press release | Business Wire | -1.41% | +1.77% | |
| Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway | Press release | Business Wire | +1.92% | -1.03% | |
| Form 8-K Summit Therapeutics Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -10.29% | -13.14% | |
| AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics | Press release | Business Wire | -10.29% | -13.14% | |
| HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026 | Press release | Business Wire | -0.82% | +0.88% | |
| Form 8-K Summit Therapeutics Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | -4.18% | |
| Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients | Press release | Business Wire | +0.33% | -4.18% | |
| Form 8-K Summit Therapeutics Inc. For: Sep 13 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | +2.33% | |
| Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China | Press release | Business Wire | +0.83% | +2.33% | |
| Form 8-K Summit Therapeutics Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +4.77% | +10.37% | |
| Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China | Press release | Business Wire | +4.77% | +10.37% | |
| Form 8-K Summit Therapeutics Inc. For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | -0.00% | -3.13% | |
| Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China | Press release | Business Wire | -0.00% | -3.13% | |
| Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology | Press release | Business Wire | +0.90% | +0.68% | |
| Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer | Press release | Business Wire | +1.04% | -2.01% | |
| Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty | Press release | GlobeNewswire | -2.52% | +0.43% | |
| Form 8-K Summit Therapeutics Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -2.73% | |
| Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer | Press release | Business Wire | -0.25% | -2.73% | |
| Form 10-Q Summit Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.15% | +0.44% | |
| Form 8-K Summit Therapeutics Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | +0.44% | |
| Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 | Press release | Business Wire | -0.15% | +0.44% | |
| Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer | Press release | Business Wire | +0.88% | +1.70% | |
| Form 8-K Summit Therapeutics Inc. For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | -2.90% | |
| Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study | Press release | Business Wire | +0.95% | -2.90% | |
| Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 | Press release | Business Wire | -1.03% | -7.65% | |
| Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. | Press release | Business Wire | -0.16% | +1.11% | |
| Form 8-K Summit Therapeutics Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -1.53% | |
| Form 8-K Summit Therapeutics Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -4.18% | |
| Form S-3ASR Summit Therapeutics Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +4.72% | -0.69% | |
| Summit Therapeutics Announces Proposed Public Offering of Common Stock | Press release | Business Wire | +4.72% | -0.69% | |
| Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference | Press release | Business Wire | -1.02% | -3.08% | |
| Form 8-K Summit Therapeutics Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | +2.17% | |
| Form 8-K Summit Therapeutics Inc. For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -6.45% | -6.21% | |
| Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | Press release | Business Wire | -6.45% | -6.21% | |
| Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 | Press release | Business Wire | -6.45% | -6.21% | |
| Form 10-Q Summit Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.31% | +0.59% | |
| Form 8-K Summit Therapeutics Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | +0.59% | |
| Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 | Press release | Business Wire | -2.31% | +0.59% | |
| Form ARS Summit Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.83% | +2.11% | |
| Form DEF 14A Summit Therapeutics Inc. For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -1.83% | +2.11% | |
| Form DEFA14A Summit Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.83% | +2.11% | |
| Form PRE 14A Summit Therapeutics Inc. For: Apr 06 | SEC filing · Form PRE | SEC EDGAR | -0.69% | +3.56% | |
| Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 | Press release | Business Wire | -1.32% | -4.71% | |
| Summit Therapeutics to Present at Upcoming Investor Conferences | Press release | Business Wire | +2.11% | +6.28% | |
| Form 10-K Summit Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.31% | +2.15% | |
| Form 8-K Summit Therapeutics Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | +2.15% | |
| Form S-8 Summit Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.31% | +2.15% | |
| Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 | Press release | Business Wire | +2.31% | +2.15% | |
| Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 | Press release | Business Wire | +0.13% | +1.99% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SMMT section they belong to.
Where else SMMT is measured.
SMMT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
| Scholar Rock Holding Corporation (SRRK) | 425 | 0.00% | 49% |
| Koninklijke Philips N.V. NY Registry Shares (PHG) | 424 | +0.04% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Summit Therapeutics Inc.'s median reaction calculated?
Every labeled SMMT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 426 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of SMMT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SMMT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.